All News
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with polymyalgia rheumatica (PMR).
Read Article
Altered Gut Biome in Inflammatory Arthritis
d
MedPage Today
Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear. In fact, the investigato
Read Article
Predicting Inflammatory Arthritis in At-Risk Persons
The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk inflammatory arthritis (IA) and who may benefit from risk stratification and preventive measures.
Read Article
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv
Links:
Dr. John Cush RheumNow ( View Tweet)
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells from RA & PsA pts - showing clonal expansion of activated effector CD38hi,CD127−, CD8 T cells, w/ incr type I IFN-assoc transcripts https://t.co/vw2sOGL6jQ https://t.co/uDlt9dH4mQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/08qOjVJE9A https://t.co/eH6oWsB1dT
Links:
Dr. John Cush RheumNow ( View Tweet)
The Importance of Knowing Which Entheses are Involved in PsA
Dr. Eric Ruderman discusses abstract POS0027 presented at EULAR 2023 in Milan, Italy.
https://t.co/nRJfNxwDF0 https://t.co/LUgLQTIUDD
Links:
Dr. John Cush RheumNow ( View Tweet)
New Full Length from A&R:
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns
https://t.co/5pzBfiZaNt
Created with https://t.co/L5O6lHuNSY https://t.co/HvDy4b1Bg3
Links:
ACR_Journals ACR_Journals ( View Tweet)
Retrospective study of 1877
pts. W/ granulomatosis with polyangiitis (GPA) on RTX found only 23% received TMP-SMX for a median of 141 days. Prophylaxis was assoc w/ prednisone use (OR 3.96), MTX use (OR 1.48), ICU care (OR 1.95), hospitalization(OR 1.56) https://t.co/JRUC8HUwJU
Links:
Dr. John Cush RheumNow ( View Tweet)
Pain in the Neck
https://t.co/JxNBJvlekM https://t.co/vaPSDK2vHQ
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-23 Inhibitor Performance in Psoriatic Disease
A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/yNQkEwRT3W https://t.co/YG7uBpDrPP
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1
Links:
Dr. John Cush RheumNow ( View Tweet)
Link Between Vitamin D and Psoriasis Severity
More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.
https://t.co/bHnYn87wQS https://t.co/JsloVaxHd4
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid vasculitis (RV) metanalysis: RV decreased sincefrom 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/O3G4CS1pdx https://t.co/I2RVKR20lX
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
https://t.co/YmKLuhyCVG https://t.co/X2u9iCckt7
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR/ACR Guidance on HLH/MAS
A EULAR/ACR task force has established evidence based, up-to-date guidance, and expert opinion on the evaluation, management and monitoring of patients with HLH and MAS.
https://t.co/ZQQ75pyvAX https://t.co/t6lj5XaAwB
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitors Reduce Gout Flares and CV Events
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations.
https://t.co/XCh7ulamwU https://t.co/dbOAtaflmb
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/8U6DHbJybE https://t.co/e45KCd5gBL
Links:
Dr. John Cush RheumNow ( View Tweet)
MMWR: Arthritis Among Children and Adolescents
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.
https://t.co/S1dG60jJ1J https://t.co/rKQ64sopl2
Links:
Dr. John Cush RheumNow ( View Tweet)